What is Tonix Pharmaceuticals Holding Current Ratio?
Tonix Pharmaceuticals HoldingTNXP -2.75%41 Current Ratio is 6.99 as of Mar. 2026, which is 21% below its 10-year median of 8.86. GuruFocus rates TNXP with a GF Score™ of 41/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Tonix Pharmaceuticals Holding ranks better than 68.13% on this metric.
Tonix Pharmaceuticals Holding has a current ratio of 6.99. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Tonix Pharmaceuticals Holding's Current Ratio or its related term are showing as below:
TNXP'
s Current Ratio Range Over the Past 10 Years
Min: 1.15 Med: 8.86 Max: 28.73
Current: 6.99
During the past 13 years, Tonix Pharmaceuticals Holding's highest Current Ratio was 28.73. The lowest was 1.15. And the median was 8.86.
TNXP's Current Ratio is ranked better than 68.13% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs TNXP: 6.99
Tonix Pharmaceuticals Holding (NAS:TNXP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Tonix Pharmaceuticals Holding Current Ratio Related Terms
Tonix Pharmaceuticals Holding Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNXP vs ALEC, IMUX, WHWK: Current Ratio Comparison
For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonix Pharmaceuticals Holding Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Current Ratio distribution charts can be found below:
* The bar in red indicates where Tonix Pharmaceuticals Holding's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tonix Pharmaceuticals Holding (TNXP) has a Current Ratio of 6.99 as of Mar. 2026. This is 21% below median its historical median of 8.86. Over the past decade, Tonix Pharmaceuticals Holding's Current Ratio has ranged from 1.15 to 28.73. According to the industry distribution chart, Tonix Pharmaceuticals Holding ranks #450 out of 1412 companies in the Biotechnology industry, placing it in the top 31.9%.
Is Tonix Pharmaceuticals Holding's Current Ratio too high?
Tonix Pharmaceuticals Holding's current Current Ratio of 6.99 is 21% below median its 10-year median of 8.86. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 28.73. The Biotechnology industry median Current Ratio is 3.89. Tonix Pharmaceuticals Holding's value of 6.99 is 79.7% above this industry median. Based on the distribution chart, Tonix Pharmaceuticals Holding ranks #450 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Current Ratio compare to ALEC and IMUX?
According to the Biotechnology industry distribution chart, Tonix Pharmaceuticals Holding ranks #450 out of 1412 companies for Current Ratio. This puts Tonix Pharmaceuticals Holding in the upper half of its industry. The industry median Current Ratio is 3.89. Tonix Pharmaceuticals Holding's value of 6.99 is 79.7% above this benchmark. Historically, Tonix Pharmaceuticals Holding's own Current Ratio has ranged from 1.15 to 28.73 over the past decade. While the company's 10-year median is 8.86 vs. the industry median of 3.89, Tonix Pharmaceuticals Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tonix Pharmaceuticals Holding's current Current Ratio of 6.99 is 79.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tonix Pharmaceuticals Holding's current Current Ratio is 6.99, which is 21% below median its own 10-year median of 8.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $12.75 — trading 628.6% above its estimated fair value. The current Current Ratio is 6.99, which is 21% below median its 10-year median of 8.86 and 79.7% above the Biotechnology industry median of 3.89. Tonix Pharmaceuticals Holding's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Current Ratio is 6.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued.
The current stock price of $12.75 is trading 628.6% above its estimated GF Value™ of $1.75.
GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.
Key valuation signals for TNXP:
Current Ratio: 6.99 (21% below median its 10-year median of 8.86)
GF Value™: $1.75 vs. price of $12.75 (628.6% above fair value)
Industry Position: 79.7% above the Biotechnology median (#450 of 1412)
No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tonix Pharmaceuticals Holding Business Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
41GF Score
Get the complete analysis for TNXP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNXP has been successfully added to your 
